Innovest Global

Innovest Global is a diversified holding company that operates a dedicated biotechnology division primarily through its subsidiary, StemVax Therapeutics. The company's flagship healthcare project is StemVax 301, a personalized cancer immunotherapy designed to treat glioblastoma multiforme (GBM). This therapeutic approach utilizes a patient's own dendritic cells, which are primed with tumor-specific antigens to stimulate an immune response against cancer stem cells. By targeting the cells responsible for tumor regrowth, the StemVax platform aims to improve long-term survival rates and prevent recurrence in brain cancer patients. Innovest Global focuses on advancing this clinical-stage asset while managing a portfolio of industrial and energy-related businesses.